

Transport of amino acids through the placenta and their role

M. A. Grillo · A. Lanza · S. Colombatto

Received: 12 September 2007 / Accepted: 13 November 2007 / Published online: 3 January 2008
© Springer-Verlag 2007

Abstract Amino acids are transported across the human placenta mediated by transporter proteins that differ in structure, mechanism and substrate specificity. Some of them are Na⁺-dependent systems, whereas others are Na⁺-independent. Among these there are transporters composed of a heavy chain, a glycoprotein, and a light chain. Moreover, they can be differently distributed in the two membranes forming the syncytiotrophoblast. The transport mechanisms involved and their regulation are only partially known. In the placenta itself, part of the amino acids is metabolized to form other compounds important for the fetus. This occurs for instance for arginine, which gives rise to polyamines and to NO. Interconversion occurs among few other amino acids. Transport is altered in pregnancy complications, such as restricted fetal growth.

Keywords Transport systems · Glycoprotein associated transporters · Indoleamino 2,3-dioxygenase · Polyamines

Introduction

Glucose is the fetus's main fuel and lipids are also important. Amino acids are vital for its development as they are the components of proteins and are essential precursors for the synthesis of non-protein substances, such as nitric oxide, polyamines, neurotransmitters, purine and pyrimidine nucleotides, etc.

Maternal plasma amino acid levels are 20–25% below normal as early as the first trimester. All amino acids, except tryptophan, are present in the intervillous space at concentrations 186% higher than in the maternal venous blood. This is in agreement with an active transport mechanism (Camelo et al. 2004).

Placental amino acid uptake is mediated by transporters on the microvillous membrane of the syncytiotrophoblast, while the efflux to the fetus is mediated by transporters on its basal membrane. The placental barrier between the maternal and the fetal circulation is the singular epithelium called the syncytiotrophoblast, whose apical microvillous membrane is in direct contact with the maternal venous blood of the intervillous space, whereas the basal membrane is in front of the fetal circulation through the umbilical circle into the placental villi. The placenta continues to grow and differentiate during pregnancy and its efficiency is enhanced by a tenfold increase in the volume of its villi and an increase from 0.08 to 12.5 m² in the area of their enveloping trophoblast accompanied by a reduction of its thickness from 18.9 to 4.1 μm and in the distance between the maternal and foetal circulation from 55.9 to 4.8 μm (Myatt 2006).

The two membranes contain different types of amino acid transporters.

Table 1 illustrates the transport systems of the placenta divided according to their structure and function, and the amino acids involved. Several transporters are monomeric and usually polytopic proteins. The Na⁺-independent transporters comprise heterodimeric transporters composed of a heavy chain, a glycoprotein (the best known are rBAT and 4F2hc), and a light chain linked by a disulfide bond. The heavy chains are thought to have only one transmembrane helix, whereas the light chains are believed to have 12 transmembrane domains.

M. A. Grillo (✉) · A. Lanza · S. Colombatto
Dipartimento di Medicina e Oncologia Sperimentale,
Sezione di Biochimica, Università di Torino,
Via Michelangelo 27, 10126 Torino, Italy
e-mail: mariaangelica.grillo@unito.it

Table 1 Amino acid transport systems in the placenta

Transport systems	Protein	Substrates
Na ⁺ -dependent systems		
A	SNAT(1, 2, 4)	Alanine, Serine, Proline, Glycine
ASC	ASCT(1, 2)	Alanine, Serine, Cystine
N	SN1	Histidine, Asparagine, Glutamine
X _{GA} ⁻	EAAT(1–3)	Glutamate, Aspartate
β	TAUT	Taurine
B ^{o,+}	ATB ^{o,+}	Cationic and neutral amino acids
GLY	GLYT1	Glycine and Sarcosine
Cationic amino acid transport systems		
y ⁺	CAT 1–4	Cationic amino acids
Glycoprotein associated transport systems		
asc	asc1/4F2hc	Small neutral amino acids and D-serine
b ^{o,+}	b ^{o,+} /rBAT	Cationic and neutral amino acids
L	LAT1,LAT2/4F2hc	Neutral amino acids, branched-chain amino acids and tryptophan
y ⁺ L	y ⁺ LAT1/4F2hc	Cationic amino acids
x _c ⁻	xCT/4F2hc	Glutamate/cystine exchange
T	TAT1	Aromatic amino acids

Na⁺-dependent amino acid transport systems

System A is encoded by three genes that give rise to three subtypes of neutral amino acid transporters (SNAT): SNAT1, SNAT2 and SNAT4. The three isoforms are highly homologous. Gene expression varies from one tissue to another. SNAT2 alone is ubiquitous in mammalian tissues. SNAT1 is expressed in heart, brain and placenta. SNAT4, initially found in the liver only, has now been demonstrated in the placenta also (Desforges et al. 2006). SNAT4 mRNA expression is higher in the first trimester, whereas its protein expression is higher at term. Its location in the two syncytiotrophoblast membranes points to its involvement in amino acid transport across the placenta.

These transporters are involved in the transport of serine and glycine: serine is predominantly transported by system A (SNAT1 and SNAT2) and system L, glycine by system A and system Gly (Dicke et al. 1993). However, uptake of serine is much higher than that of glycine, despite the greater demand for glycine as opposed to serine for protein synthesis (Lewis et al. 2007).

The ASC system mediates transport of the short-chain neutral amino acids, such as alanine, serine, cysteine. Two isoforms are known, ASCT1 and ASCT2. Both are expressed in the human placenta and located in the basal membrane only.

System N is restricted to glutamine, asparagine and histidine. Two isoforms are known in human tissues, but their presence in the human placenta is contested. (Karl et al. 1990; Novak et al. 1997).

The anionic amino acids glutamate and aspartate are not conveyed across the placenta (Hoeltzli et al. 1990), though X_{AG}⁻, a Na⁺ and K⁺ dependent transport system for these amino acids is present in both syncytiotrophoblast membranes (Carriapa et al. 2003). Its five isoforms are called Excitatory Amino Acid Transporters (EAAT 1–5). EAAT 1, 2 and 3 are found in the placenta: isoform 3 predominates in the apical membrane; isoforms 1 and 2 are predominant in the basal membranes. However, since glutamate and aspartate concentrations are much higher in the placenta than in the fetal or in the maternal circulation, glutamine is evidently taken up by the fetal liver and metabolized to glutamate, which is then taken up by the placenta (Jansson 2001).

System β transports β-amino acids. Of these, taurine is essential during fetal life and vital for fetal growth. It is not involved in protein synthesis, but utilized for other processes. Its concentration in the placenta is much higher than in the maternal blood due to the presence of an active Na⁺ and Cl⁻-dependent transport system in the microvillous membrane, with a 2:1:1 Na⁺/Cl⁻/taurine stoichiometry (Ramamoorthy et al. 1994). Transport in the basal membrane is much less active. However these transporters act in conjunction with an Na⁺-independent system. The lower plasma taurine concentration noted in intrauterine growth restriction (IUGR) fetuses is apparently due to reduced transporter activity (Norberg et al. 1998), perhaps as the result of dysregulation, since experiments in YAR cells have shown that the taurine transporter is inhibited by activation of protein kinase C (Kulanthaivel et al. 1991).

Another cationic and neutral amino acid transport system is $B^{0,+}$ (B for broad specificity) (Van Winkle et al. 1990). Leucine transported by this system (Van Winkle et al. 2006) triggers signalling by the “mammalian target of rapamycin” (mTOR), a serine/threonine kinase needed for differentiation of motile trophoblasts. Moreover it is suggested that this system regulates the penetration stage of blastocyst implantation with possible long-term consequences. The importance of mTOR is illustrated by the demonstration by Roos et al. (2007) that mTOR protein is expressed in the transporting epithelium of the human placenta and regulates amino acid transport, though not that by system A.

System Gly is specific for glycine and its methylated derivative, sarcosine.

Cationic amino acid transport systems

Cationic amino acids are transported by four groups of transporter. The first is the y^+ family composed of five confirmed members CAT1, CAT2A, CAT2B, CAT3 and CAT4 (Closs et al. 2006). The CAT1 system is considered to be the major cationic transport system in the placenta (Ayuk et al. 2000). It is a sodium-independent, low affinity and high capacity system. An other system, y^+L is present in the basal membrane and in lower amount also in the microvillous. This system is less sensitive to membrane potential differences (Eleno et al. 1994). The electrical potential gradient across the plasma membrane of the trophoblast provides a strong driving force for the accumulation of the cationic amino acids inside the cell (White 1985). On hyperpolarization the permeability of cationic amino acids of the apical membrane increases more for system y^+ than for system y^+L . This will allow rapid entry of amino acids down the prevailing electrical potential into the cell. Then amino acids will leave the cell through the y^+L system relatively insensitive to membrane potential. This is possible as this system can perform an exchange with neutral amino acids in the presence of Na^+ .

The other systems are $b^{0,+}$, Na^+ -independent, and $\beta^{0,+}$, Na^+ -dependent. CAT2A is mainly expressed in liver, while CAT2B, which has a much higher affinity, is induced in many types of cells. By contrast with CAT1, CAT2A is insensitive to transstimulation. Human CAT3 is specific for cationic amino acids.

Glycoprotein-associated transport systems

System asc transports small neutral amino acids and is inhibited by 2-aminoisobutyric acid. It also transports

D-serine, which acts as a co-agonist of the NMDA receptors in the central nervous system (Mothet et al. 2000). Asc-1 (the only one found in humans, Palacin et al. 2005), combined with 4F2hc, preferentially operates in an exchange mode (Fukasawa et al. 2000), although not exclusively.

Another heterodimeric system is $b^{0,+}$, formed by a light chain combined with the glycoprotein rBAT. This transporter mediates the Na^+ -independent uptake of cationic amino acids and cystine. Its function in the placenta is still under discussion (Jansson 2001).

System L (L for leucine preferring) is expressed in the microvillous and the basal membrane and regarded as the main route for the transport of branched-chain and aromatic amino acids. Two isoforms, LAT1 and LAT2, with different affinities for the substrates, most neutral amino acids, branched as well as aromatic, have long been known. Recent additions are LAT3 identified in human hepatocarcinoma cells (Babu et al. 2003), and LAT4 in the human placenta also (Bodoy et al. 2005).

Other heterodimeric transporters are those of the y^+L family. Its two isoforms y^+LAT1 and y^+LAT2 exchange cationic amino acids against neutral amino acids plus Na^+ (Verrey et al. 2000). y^+LAT1 is present in the placenta.

System x_c^- transports cystine and glutamate. It provides cysteine for glutathione synthesis and has other functions (Christensen 1990). This system is almost ubiquitous in cultured mammalian cell lines. Its physiological role appears to be the entry of cystine and the exit of glutamate. As cysteine is the rate-limiting precursor for glutathione synthesis, the intracellular level of glutathione is regulated by x_c^- activity. This system is formed of two proteins, 4F2hc and a novel protein of 502 amino acids with 12 putative transmembrane domain (Sato et al. 1999), the so-called xCT light chain.

L-tyrosine transport in the human placenta is different in isolated brush borders and basal membrane vesicles: in the first case, system L is thought to be responsible, in the second, system T (Kudo and Boyd 1990). TAT1 (T-type amino acid transporter 1) has since been shown to display Na^+ -independent and low affinity transport of aromatic amino acids (tryptofan, tyrosine, phenylalanine). As TAT1 mRNA is strongly expressed in the placenta, TAT1 may be responsible for its system T activity (Kim et al. 2001).

For other tissues, it has been suggested that TAT1 controls the amino acid efflux via LAT2-4F2hc. This would suggest that by allowing aromatic amino acids to efflux, TAT1 provides the obligatory exchanger LAT2-4F2hc with influx substrates and therefore controls the net efflux of other neutral amino acids (Ramadan et al. 2007).

Metabolism of amino acids in the placenta

The fate of the serine taken up is not known. Serine hydroxymethyl-transferase, which transforms serine into glycine, is very low in the placenta (Lewis et al. 2005). Moreover, the source of glycine, which is required by the fetus in large amounts, remains to be established. It may be derived from serine that has crossed the placenta, or from the serine synthesised in the fetus from glucose via 3-phosphoglycerate. The second mechanism would increase the amount of methylenetetrahydrofolate needed for the synthesis of purine nucleotides. According to Cetin (2001), the fetal liver is also able to transform glycine into serine by the combined action of serine hydroxymethyltransferase and glycine dehydrogenase.

Arginine has several functions. It is used for protein synthesis, the synthesis of nitric oxide (NO) by nitric oxide synthases (NOS) and the synthesis of polyamines through the formation of ornithine: this can also be a precursor of proline.

Nitric oxide is an important endogenous regulator of vascular tone, in health and disease. This occurs in the placental regulation also. NOS isoforms are actively expressed in the syncytiotrophoblast. Activity appears to be mainly Ca^{++} -dependent, due therefore to eNOS. However iNOS is the predominant isoform in the human pregnant uterus (Ali et al. 1997) and iNOS mRNA is detected early in the syncytiotrophoblast and placental artery smooth muscle (Baylis et al. 1999).

A functional link has been suggested between CAT1 and eNOS, and CAT2B and iNOS, ensuring appropriate delivery of L-arginine to these NOS isoforms (Casanello et al. 2007). Higher expression of the human transporter hCAT1 mRNA and eNOS has been observed in gestational diabetes. It is suggested that this results from an increase of extracellular adenosine level. Activation of protein kinases would then activate arginine transport (San Martin and Sobrevia 2006; Vasquez et al. 2004).

When arginine is metabolized by arginase, ornithine and urea are formed. Two forms of arginase are known: arginase I, located in cytotrophoblasts only, and arginase II is also located in syncytiotrophoblasts where eNOS is equally present, which means that the two enzymes compete for the substrate, arginine. The ornithine thus formed can be used for polyamine synthesis. It has been shown that polyamines play essential roles in the maintenance of early pregnancy. And in ovine placenta it has been shown that in these conditions ornithine decarboxylase (ODC), the regulatory enzyme of polyamine synthesis, and arginase activities and polyamine concentration were highest (Kwon et al. 2003). Moreover, experiments performed by administering difluoromethylornithine (DFMO), an ODC inhibitor, to rats have shown that placental weight, ODC activity and DNA

are significantly decreased. Depression of ODC activity has been postulated as the major cause of IUGR induced in rats by DFMO (Ishida et al. 2002).

Polyamines are also taken up, although the identity of the transporter(s) is still unknown (Phanstiel et al. 2007). In the intestinal epithelial cells only polyamines have been suggested to be taken up by a y^+ unknown transporter utilized by lysine also (Sharpe and Seidel 2005). Experiments performed in JAR human placental choriocarcinoma cells have shown that they are taken up and released by an independent mechanism. Ornithine decarboxylase and spermidine/spermine acetyltransferase (SSAT) activities and the intake and output transport rates are much higher than in e.g. L1210 cells. As a result, a much higher concentration of polyamines is observed. The uptake appears to be regulated by an inhibitory protein, possibly ODC-AZ. Moreover, protein kinase C (PKC) appears to be involved (Fontana et al. 1996). In other cells, too, such as astrocytes, some isoforms of the glutamate transporter would seem to be regulated by PKC (Susarla et al. 2004). It is now clear that systems y^+ and y^+L are downregulated by PKC in different cell lines (Rotmann et al. 2007).

In the human placenta, arginase activity is highest in the first trimester and then decreases. It is suggested that this early elevation may be responsible for proliferation of human trophoblasts by increasing polyamine production (Ishikawa et al. 2007).

Surprisingly, placental polyamine synthesis is different in an other mammal: in the porcine placenta it occurs mainly from proline through the action of proline oxidase and ornithine aminotransferase, whereas arginase is not detectable (Wu et al. 2005).

Tryptophan transport across the syncytiotrophoblast is an important function of system L, whereas part of the tryptophan taken up is transported across the basal membrane by means of system LAT-2 and system y^+L (Kudo and Boyd 2001a). System y^+L is a high affinity route whose importance increases when the tryptophan concentration is low. Both systems display “trans” effects with other extracellular amino acids (Kudo and Boyd 2001b). Yet another part of the tryptophan taken up is metabolized by indoleamine 2,3-dioxygenase (IDO), an enzyme thought to suppress the maternal immune response to the allogenic murine fetus and hence required to prevent rejection of the fetus by maternal T cells. As blockers of the activity of tryptophan inhibit its transport by system L and vice versa, its uptake by system L is thought to be rate-limiting and of importance in the maintenance of pregnancy (Wagner et al. 2001). Cytokines, such as interferon γ , induce IDO and tryptophanyl-tRNA synthesis is increased at the same time with the result that the ability of the placenta to synthesise protein is not impaired (Mellor and Munn 1999).

However, the idea that IDO prevents rejection of the fetus and that this is due to a decrease in tryptophan concentration has been followed by another suggestion, namely that the tryptophan metabolites 3-hydroxy-kynurenine, 3-hydroxy anthranilic acid and to a lesser extent kynurenine and picolinic acid, which were shown to inhibit T-cell proliferation (Frumento et al. 2002; Terness et al. 2002) are responsible. It has also been suggested that NO can have a role, either affecting the immune system directly or the IDO pathway (Gonzalez et al. 2004). At low NO production, therefore, IDO activity would be increased, whereas in the event of inflammation iNOS would be induced and high NO production would inactivate IDO and favour the immune response (Lopez et al. 2006). However, it has not yet been shown that IDO has an immunoregulatory role *in vivo* (Terness et al. 2006).

Interconversion also occurs between glutamine and glutamate. Glutamine is taken up by the fetal liver (Marconi et al. 1989). About 45% is converted to glutamate (Battaglia 2000) and utilized within the uterus and placenta, where it gives rise to NADPH useful for other syntheses, and to ammonia, which will be excreted (Cetin 2001). However in the sheep fetal liver at parturition a striking reduction in glutamate output was observed, leading to a marked decrease in placental glutamate uptake (Battaglia 2000).

Part of the glutamate is also used with cysteine and glycine to form glutathione. This synthesis is possible in the placenta since it contains both the enzymes required, namely glutamyl-cysteine synthetase and glutathione synthetase (Wellner et al. 1974). The observation has been confirmed in mouse embryo, where the mRNA for both the subunits necessary for glutamate-cysteine synthetase have been detected, and also the protein subunit possessing catalytic activity (Diaz et al. 2002). However, the protein expression is strictly regulated (Diaz et al. 2004). This synthesis is important, as GSH is necessary for many functions, such as detoxification of xenobiotics, removal of hydrogen peroxide and free radicals, maintenance of free protein sulphhydryl groups, glutathionylation of several proteins, etc. All the enzymes involved, i.e. glutathione peroxidase, GSSG reductase, GSH S-transferase (GSTP1-1) and gamma glutamyltranspeptidase are present in the human placenta.

GSTP1-1 has other functions. It inhibits c-Jun N-terminal kinase signalling through interaction with the C terminus (Wang et al. 2001) and may thus be supposed to participate in regulation of the cell cycle, DNA repair and apoptosis (Adler et al. 1999). However GSH used by peroxidase and reductase is regenerated, whereas that used by the transferase is consumed and must be replaced by resynthesis from its amino acids. Moreover, it has been suggested that glutathionylated proteins can also be formed by other mechanisms, that is in response to oxidative and

nitrosative stress (Klatt and Lamas 2000). Here, too, however, GSH is consumed.

Since GSTP1-1, like the other human GST classes, has been shown to bind NO, they have been proposed as intracellular NO carriers or scavengers (Cesareo et al. 2005).

Branched-chain amino acids are transaminated in the placenta and give rise to glutamate. Leucine can also be deaminated and give rise to its ketoacid. Then ammonia is released to the maternal circulation, whereas the ketoacid and leucine itself are transferred to the fetus. However states of protein accretion and positive nitrogen balance are associated with downregulation of the rate of transamination of leucine (Kahlan and Parimi 2006).

Conclusion

These findings show that the transport of amino acids through the placenta is essential for the fetus. However, the relationship between placental function and the fetal growth rate deserves further study. The plasma amino acid concentration of IUGR delivering babies at birth is higher than in the case of appropriately grown for gestational age babies (Malandro et al. 1996; Cetin et al. 1996). Jansson et al. (2006), however, have shown that IUGR in human pregnancy is associated with down-regulation of transporter system A and that this reduction precedes IUGR. According to Shibata et al. (2006) an enhanced placental renin-angiotensin system is a potential contributor to the reduced system A amino acid transport in IUGR. It must not be forgotten, however, that the transport of any amino acid from placenta to fetus depends on the presence of inhibitory amino acids (Jozwik et al. 2004). Therefore administration of amino acids would be useful, provided due considerations were given to the right composition of their mixture.

References

- Adler V, Yin Z, Fuchs SV, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z (1999) Regulation of JNK signaling by GSTp. *EMBO J* 18:1321–1334
- Ali M, Buhimschi I, Chwalisz K, Garfield RE (1997) Changes in expression of the nitric oxide synthase isoforms in rat uterus and cervix during pregnancy and parturition. *Mol Hum Reprod* 3:995–1003
- Ayuk PTY, Sibley CP, Donnai P, D'Souza S, Glazier JD (2000) Development and polarization of cationic amino acid transporters and regulators in the human placenta. *Am J Physiol* 278:C1162–C1171
- Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, Jutabha P, Li Y, Ahmrd N, Sakamoto S, Anzai N, Nagamori S, Endou H (2003) Identification of a novel system L amino acid

- transporter structurally distinct from heterodimeric amino acid transporters. *J Biol Chem* 278:43838–43845
- Battaglia FC (2000) Glutamine and glutamate exchange between the fetal liver and the placenta. *J Nutr* 130:974S–977S
- Baylis SA, Srijbos PJLM, Russell RJ, Rijhsinghani A, Charles IG, Weiner CP (1999) Temporal expression of inducible nitric oxide synthase in mouse and human placenta. *Mol Hum Reprod* 5:277–286
- Bodoy S, Martin L, Zorzano A, Palacin M, Estévez R, Bertran J (2005) Identification of LAT4, a novel amino acid transporter with system L activity. *J Biol Chem* 280:12002–12011
- Camelo JS Jr, Jorge SM, Martinez FE (2004) Amino acid composition of parturient plasma, the intervillous space of the placenta and the umbilical vein of term newborn infants. *Braz J Med Biol Res* 37:711–717
- Cariappa R, Heath-Monnig E, Smith CH (2003) Isoforms of amino acid transporters in placental syncytiotrophoblast: plasma membrane localization and potential role in maternal/fetal transport. *Placenta* 24:713–726
- Casanello P, Escudero C, Sobrevia L (2007) Equilibrative nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelium dysfunction in human pregnancy diseases. *Curr Vasc Pharmacol* 5:69–84
- Cesareo E, Parker LJ, Pedersen JZ, Nuccetelli M, Mazzetti AP, Pastore A, Federici G, Caccuri AM, Ricci G, Adams JJ, Parker MW, Lo Bello M (2005) Nitrosylation of human glutathione transferase P1–1 with dinitrosyl diglutathionyl iron complex in vitro and in vivo. *J Biol Chem* 280:42172–42180
- Cetin I (2001) Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo. *Ped Res* 49:148–154
- Cetin I, Ronzoni S, Marconi AM, Perugino G, Corbetta C, Battaglia F, Pardi G (1996) Maternal concentration and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancy. *Am J Obstet Gynecol* 174:1575–1583
- Christensen HN (1990) Role of amino acid transport and counter-transport in nutrition and metabolism. *Physiol Rev* 70:43–77
- Closs EI, Boissel J-P, Habermeyer A, Rotmann A (2006) Structure and function of cationic amino acid transporters (CATs). *J Membr Biol* 213:67–77
- Desforges M, Lacey HA, Glazier JD, Greenwood SL, Mynett KJ, Speake PF, Sibley CP (2006) SNAT4 isoform of system A amino acid transporter is expressed in human placenta. *Am J Physiol Cell Physiol* 290: C305–C312
- Diaz D, Krejsa CM, Kavanagh TJ (2002) Expression of glutamate-cysteine ligase during mouse development. *Mol Reprod Dev* 62:83–91
- Diaz D, Krejsa CM, White CC, Charleston JS, Kavanagh TJ (2004) Effect of methylmercury on glutamate-cysteine ligase expression in the placenta and yolk sac during mouse development. *Reprod Toxicol* 19:117–129
- Dicke JM, Verges D, Kelley LK, Smith CH (1993) Glycine uptake by microvillous and plasma basal membrane vesicles from term human placentae. *Placenta* 14:85–89
- Eleno N, Devés R, Boyd CA (1994) Membrane potential dependence of the kinetics of cationic amino acid transport systems in human placenta. *J Physiol* 479:291–300
- Fontana L, Cravanzola C, Colombatto S, Grillo MA (1996) JAR human placental choriocarcinoma cells actively synthesize, take up and release polyamines. *Cell Biochem Funct* 14:173–180
- Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. *J Exp Med* 196:459–468
- Fukasawa Y, Segawa H, Kim JY, Chairoungdua A, Kim DK, Matsuo H, Cha SH, Endou H, Kanai Y (2000) Identification and characterization of a Na⁺-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids. *J Biol Chem* 275:9690–9698
- González A, López AS, Alcázar JL, López-Moratalla N (2004) Does nitric oxide play a role in maternal tolerance towards the fetus? *J Physiol Biochem* 60:227–238
- Hoeltzli SD, Kelley LK, Moe AJ, Smith CH (1990) Anionic amino acid transport systems in isolated basal plasma membrane of human placenta. *Am J Physiol* 259:C47–C55
- Ishida M, Hiramatsu Y, Masuyama H, Mizutani Y, Kudo T (2002) Inhibition of placental ornithine decarboxylase by DL-a-difluoro-methylornithine causes fetal growth restriction in rat. *Life Sci* 70:1395–1405
- Ishikawa T, Harada T, Koi H, Kubota T, Azuma H, Aso T (2007) Identification of arginase in human placental villi. *Placenta* 28:133–138
- Jansson T (2001) Amino acid transporters in the human placenta. *Pediatr Res* 49:141–147
- Jansson N, Petersson J, Haafiz A, Ericsson A, Palmberg I, Tranberg M, Ganapathy V, Powell TL, Jansson T (2006) Down-regulation of placental transport of amino acids precedes the development of intrauterine growth restriction in rats fed a low protein diet. *J Physiol* 576:935–946
- Józwik M, Teng C, Wilkening RB, Meschia G, Battaglia FC (2004) Reciprocal inhibition of umbilical uptake within groups of amino acids. *Am J Physiol Endocrinol Metab* 286:E376–E383
- Kalhan SC, Parimi PS (2006) Transamination of leucine and nitrogen accretion in human pregnancy and the newborn infant. *J Nutr* 136:281S–287S
- Karl PI, Tkaczewski H, Fisher SE (1990) Characteristics of histidine uptake by human placental microvillous membrane vesicles. *Pediatr Res* 25:19–26
- Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H (2001) Expression cloning of a Na⁺-independent aromatic amino acid transporter with structural similarity to H⁺/monocarboxylate transporters. *J Biol Chem* 276:17221–17228
- Klatt P, Lamas S (2000) Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. *Eur J Biochem* 267:4928–4944
- Kudo Y, Boyd CAR (1990) Human placental L-tyrosine transport: a comparison of brush-border and basal membrane vesicles. *J Physiol* 426:381–395
- Kudo Y, Boyd CAR (2001a) Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicle. *J Physiol* 531:405–416
- Kudo Y, Boyd CAR (2001b) The physiology of human evasion during pregnancy; the critical role of placental tryptophan metabolism and transport. *Pflügers Arch/Eur J Physiol* 442:639–641
- Kulanthaivel P, Cool DR, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapathy V (1991) Transport of taurine and its regulation by protein kinase C in the JAR human placental choriocarcinoma cell line. *Biochem J* 277:53–58
- Kwon H, Wu G, Bazer FW, Spencer TE (2003) Developmental changes in polyamine levels and synthesis in the ovine conceptus. *Biol Reprod* 69:1626–1634
- Lewis RM, Godfrey KM, Jackson AA, Cameron IT, Hanson MA (2005) Low serine hydroxymethyltransferase activity in the human placenta has important implications for fetal glycine supply. *J Clin Endocrinol Metab* 90:1594–1598
- Lewis RM, Glazier J, Greenwood SL, Benneu EJ, Godfrey KM, Jackson AA, Sibley CP, Cameron IT, Hanson MA (2007) L-serine uptake by human placental microvillous membrane vesicles. *Placenta* 28:445–452
- López AS, Alegre E, Diaz A, Mugueta C, González A (2006) Bimodal effect of nitric oxide in the enzymatic activity of

- indoleamine 2,3-dioxygenase in human monocytic cells. *Immunol Lett* 106:163–171
- Malandro MS, Beveridge MJ, Kilberg MS, Novak DA (1996) Effect of a low-protein diet-induced intrauterine growth retardation on rat placental amino acid transport. *Am J Physiol* 271:C295–C303
- Marconi AM, Battaglia FC, Meschia G, Sparks JW (1989) A comparison of amino acid arteriovenous differences across the liver and placenta of the fetal lamb. *Am J Physiol* 257:E909–E910
- Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? *Immunol Today* 20:469–47
- Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, Rogawski MA, Snyder SH (2000) D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. *Proc Natl Acad Sci* 97:4926–4931
- Myatt L (2006) Placental adaptive responses and fetal programming. *J Physiol* 572:25–30
- Norberg S, Powell TL, Jansson T (1998) Intrauterine growth restriction is associated with a reduced activity of placental taurine transporters. *Pediatr Res* 44:233–238
- Novak DA, Beveridge MJ (1997) Glutamine transport in human and rat placenta. *Placenta* 18:379–386
- Palacin M, Nunes V, Font-Litjós M, Jiménez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadaló L, Chillarón J, Zorzano A (2005) The genetics of heteromeric amino acid transporters. *Physiol* 20:112–124
- Phanstiel O IV, Kaur N, Delcros J-G (2007) Structure-activity investigations of polyamine-anthracene conjugates and their uptake via the polyamine transporter. *Amino Acids* 33:305–313
- Ramadan T, Camargo SMR, Herzog B, Bordin M, Pos M (2007) Recycling of amino acids via TAT1 allows efflux of neutral amino acids via LAT2-4F2hc exchanger. *Pflüger Arch - Eur J Physiol* 454:507–516
- Ramamoorthy S, Leibach FH, Mahesh V, Han H, Yang-Feng T, Blakely RD, Ganapathy V (1994) Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta. *Biochem J* 300:893–900
- Roos S, Jansson NL, Palmberg I, Säljö K, Powell YL, Jansson T (2007) Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted foetal growth. *J Physiol* 582:449–459
- Rotmann A, Simon A, Martiné U, Habermeier A, Closs EI (2007) Activation of classical protein kinase C (PKC) decreases transport via systems y^+ and y^+L . *Am J Physiol Cell Physiol* 292:C2259–C2268
- San Martin R, Sobrevia L (2006) Gestational diabetes and the adenosine/L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. *Placenta* 27:1–10
- Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. *J Biol Chem* 274:11455–11458
- Sharpe JG, Seidel ER (2005) Polyamines are absorbed through a y^+ amino acid carrier in rat intestinal epithelial cells. *Amino Acids* 29:245–253
- Shibata E, Powers RW, Rajakumar A, von Versen-Höyneck F, Gallaher MJ, Lykins DL (2006) Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation. *Am J Physiol Endocrinol Metab* 291:E1009–E1016
- Susarla BTS, Seal RP, Zelenia O, Watson DJ, Wolfe JH, Amara SG, Robinson MB (2004) Differential regulation of GLAST immunoreactivity and activity by protein kinase C: evidence for modification of amino and carboxyl termini. *J Neurochem* 91:1151–1163
- Terness P, Bauer TM, Röse L, Dufter C, Watzlik A, Simon H, Opelz G (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. *J Exp Med* 196:447–457
- Terness P, Chuang J-J, Opelz G (2006) The immunoregulatory role of IDO-producing human dendritic cells revisited. *Trends Immunol* 27:68–73
- Van Winkle LJ, Campione AL, Farrington BH (1990) Development of system B $^{0,+}$ and a broad-scope Na $^+$ -dependent transporter of zwitterionic amino acids in preimplantation mouse conceptuses. *Biochim Biophys Acta* 1025:225–233
- Van Winkle LJ, Tesch JK, Shah A, Campione AL (2006) System B $^{0,+}$ amino acid transport regulates the penetration stage of blastocyst implantation with possible long-term developmental consequences through adulthood. *Hum Reprod Update* 12:145–157
- Vásquez G, Sanhueza F, Vásquez R, González M, San Martin R, Casanello P, Sobrevia L (2004) Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. *J Physiol* 560:111–122
- Verrey F, Meier C, Rossier G, Kühn L (2000) Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity. *Pflügers Arch/Eur J Physiol* 440:503–512
- Wagner CA, Lang F, Bröer S (2001) Function and structure of heterodimeric amino acid transporters. *Am J Physiol Cell Physiol* 281:C1077–C1093
- Wang T, Arifoglu P, Ronai Z, Tew KD (2001) Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C-terminus. *J Biol Chem* 276:20999–21003
- Wellner VP, Sekura R, Meister A., Larsson A (1974) Glutathione synthetase deficiency, an inborn error of metabolism involving the γ -glutamyl cycle in patients with oxoprolinuria (pyroglutamic aciduria). *Proc Natl Acad Sci* 71:2505–2509
- White MF (1985) The transport of cationic amino acids across the plasma membrane of mammalian cells. *Biochem Biophys Acta* 822:355–374
- Wu G, Bazer FW, Hu J, Johnson GA, Spencer TE (2005) Polyamine synthesis from proline in the developing porcine placenta. *Biol Reprod* 72:842–850